While research continues to evolve, the consistent results seen in studies and anecdotal reports from users suggest BPC-157 deserves consideration as part of a comprehensive approach to healing and recovery
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
They cite a lack of research
How should Tesamorelin be stored
We note that there were no claims for the service in CY 2024 for us to consider in our analysis
The 0.9% benzyl alcohol preservative inhibits bacterial growth, allowing continued use across a 28-day window
